The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

被引：3

作者：

Duan, Minghui ^{[1
]}

Ma, Lan ^{[2
]}

Wu, Qiuling ^{[3
]}

Liang, Hong ^{[4
]}

Wang, Wei ^{[5
]}

Wu, Shaoling ^{[5
]}

Mu, Lijun ^{[6
]}

Lin, Hai ^{[7
]}

Zhou, Hebing ^{[8
]}

Shi, Hong-Xia ^{[9
]}

Wang, Jinghua ^{[10
]}

Jing, Hongmei ^{[2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[2] Peking Univ Third Hosp, Beijing, Peoples R China

[3] Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[4] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China

[5] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao, Peoples R China

[6] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[7] First Hosp Jilin Univ, Dept Hematol, Jilin, Jilin, Peoples R China

[8] Capital Med Univ, Beijing Luhe Hosp, Dept Hematol, Beijing, Peoples R China

[9] Peking Univ, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol,Peoples Hosp, Beijing, Peoples R China

[10] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188037

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
Durrant, Simon T.
Nagler, Arnon
Vannucchi, Alessandro M.
Lavie, David
Chuah, Charles
Passamonti, Francesco
Gisslinger, Heinz
le Coutre, Philipp
Gopalakrishna, Prashanth
Mahuzier, Bruyere
Mo, Shuyuan
Martinez-Lopez, Joaquin
BLOOD, 2015, 126 (23)
[42] Efficacy and Safety of Benvitimod in Patients With Palmoplantar Pustulosis: An Open-Label, Multicenter, Prospective Study
Wang, Guangping
Zhang, Shuai
Yan, Huimin
Qi, Fang
Zhang, Bingxin
Li, Yan
Wang, Hongmei
Song, Jingna
Wang, Siyao
Zeng, Sanwu
Ji, Liming
DERMATOLOGIC THERAPY, 2024, 2024
[43] Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
Guglielmelli, Paola
Palandri, Francesca
Selleri, Carmine
Cilloni, Daniela
Mendicino, Francesco
Mazza, Patrizio
Pastore, Domenico
Palumbo, Giuseppe A.
Santoro, Marco
Pavone, Vincenzo
Impera, Stefana
Morelli, Mara
Coco, Paola
Valsecchi, Diletta
Passamonti, Francesco
Breccia, Massimo
LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 189 - 198
[44] Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study
Harrison, Claire N.
Mesa, Ruben
Talpaz, Moshe
Al-Ali, Haifa Kathrin
Xicoy, Blanca
Passamonti, Francesco
Palandri, Francesca
Benevolo, Giulia
Vannucchi, Alessandro M.
Mediavilla, Clemence
Iurlo, Alessandra
Kim, InHo
Brown, Patrick
Hernandez, Christopher
Rose, Shelonitda
Wang, Jia
Kiladjian, Jean-Jacques
BLOOD, 2023, 142
[45] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Francisco Cervantes
David M. Ross
Atanas Radinoff
Francesca Palandri
Alexandr Myasnikov
Alessandro M. Vannucchi
Pierre Zachee
Heinz Gisslinger
Norio Komatsu
Lynda Foltz
Francesco Mannelli
Francesco Passamonti
Geralyn Gilotti
Islam Sadek
Ranjan Tiwari
Evren Zor
Haifa Kathrin Al-Ali
Leukemia, 2021, 35 : 3455 - 3465
[46] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
Stephen Couban
Giulia Benevolo
William Donnellan
Jennifer Cultrera
Steffen Koschmieder
Srdan Verstovsek
Gregory Hooper
Christian Hertig
Maneesh Tandon
Natalie Dimier
Vikram Malhi
Francesco Passamonti
Journal of Hematology & Oncology, 11
[47] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
Couban, Stephen
Benevolo, Giulia
Donnellan, William
Cultrera, Jennifer
Koschmieder, Steffen
Verstovsek, Srdan
Hooper, Gregory
Hertig, Christian
Tandon, Maneesh
Dimier, Natalie
Malhi, Vikram
Passamonti, Francesco
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[48] A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis
Daver, Naval G.
Kremyanskaya, Marina
O'Connell, Casey
Dao, Kim-Hien
Oh, Stephen T.
Gerds, Aaron T.
Verstovsek, Srdan
Erickson-Viitanen, Sue
Zhou, Feng
Assad, Albert
Yacoub, Abdulraheem
BLOOD, 2018, 132
[49] Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Yacoub, Abdulraheem
Borate, Uma
Rampal, Raajit
Ali, Haris
Wang, Eunice S.
Gerds, Aaron T.
Hobbs, Gabriela
Kremyanskaya, Marina
Winton, Elliott
O'Connell, Casey
Goel, Swati
Oh, Stephen
Schiller, Gary J.
Assad, Albert
Erickson-Viitanen, Sue
Zhou, Feng
Daver, Naval
BLOOD, 2021, 138
[50] Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
Francisco Cervantes
David M. Ross
Atanas Radinoff
Francesca Palandri
Alexandr Myasnikov
Alessandro M. Vannucchi
Pierre Zachee
Heinz Gisslinger
Norio Komatsu
Lynda Foltz
Francesco Mannelli
Francesco Passamonti
Geralyn Gilotti
Islam Sadek
Ranjan Tiwari
Evren Zor
Haifa Kathrin Al-Ali
Leukemia, 2021, 35 : 3626 - 3626

← 1 2 3 4 5 →